Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NDRA vs DARE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NDRA Captures Overall Composite Edge (44.7 HOLD vs 45.7 HOLD), While DARE Leads 3–1 on Growth & Valuation Pillars

NDRA Overall Winner 6-Pillar Tally: NDRA 1 – 3 DARE (2 Tie) Matrix Metrics: NDRA 4 – 4 DARE

As of Nov 16, 2026, ENDRA Life Sciences Inc. (NDRA) captures the overall head-to-head institutional edge over Dare Bioscience, Inc. (DARE) on higher Unified Composite conviction (44.7/100 HOLD vs. 45.7/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality), while DARE wins 3–1 across the 6-pillar growth and valuation breakdown. NDRA trades at $4.42 (N/M Forward P/E, 0.0% operating margin) versus DARE at $0.58 (1.3x Forward P/E, -813.4% operating margin).

  • Composite vs. Pillar Nuance: While DARE currently prints a higher short-term Unified Composite Score (45.7/100 HOLD vs. NDRA 44.7/100 HOLD), NDRA captures the overall institutional head-to-head verdict (4–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -813.4% operating margin) and revenue trajectory (+0.0% vs. +499.6% YoY).
  • Technical & Structure Timing Caution: NDRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile DARE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NDRA vs DARE
NDRA NASDAQ Head-to-Head Winner
ENDRA Life Sciences Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.42
+0.23% 1D
Market Cap $6.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.71β · 48% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 35.0 Fund 46.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.3%), weak momentum, RSI 37
RSI-14: 36.7 · SMA20: $4.75 · SMA50: $5.32
DARE NASDAQ
Dare Bioscience, Inc. Common Stock
Pharmaceutical Preparations
$0.58
-11.13% 1D
Market Cap $12.9M
TTM Revenue $1.4M
Forward P/E 1.3x
Beta / 30D Vol 1.40β · 62% Vol
Unified Composite Score
45.7 / 100 HOLD
Tech 33.0 Fund 52.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.9%), weak momentum, RSI 33
RSI-14: 33.2 · SMA20: $0.66 · SMA50: $0.73

6-Pillar Scorecard Institutional Category Breakdown (NDRA 1 – 3 DARE)

Columns: Metric · NDRA · DARE
1. Valuation Multiples DARE
Forward P/E N/M 1.3x
Trailing P/E N/M 1.3x
PEG Ratio N/M N/M
EV / Revenue N/M 1.0x
2. Growth & Scale DARE
Revenue Growth (YoY) +0.0% +499.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $1.4M
Market Cap $6.6M $12.9M
3. Profitability & Quality NDRA
Gross Margin N/A N/A
Operating Margin 0.0% -813.4%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -152.0% -2543.1%
4. Balance Sheet & Cash Flow DARE
Cash Generation (TTM) -$8.0M -$12M
Cash Flow Margin N/A N/A
Net Cash / Leverage $104,744 Net Debt (0.26x D/E) $12M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NDRA (4) vs DARE (4)
Institutional Metric NDRA DARE Criterion Row Edge
Market Capitalization
Scale
$6.6M $12.9M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M 1.3x Lower Multiple DARE
Forward P/E Ratio
Valuation
N/M 1.3x Lower Multiple DARE
Revenue Growth (YoY)
Growth
+0.0% +499.6% Higher Growth DARE
Operating Margin (TTM)
Profitability
0.0% -813.4% Higher Margin NDRA
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-152.0% -2543.1% Higher ROE NDRA
52-Week Range Position
Momentum
37% ($3–$7) 0% ($1–$4) Stronger Trend NDRA
Beta / 30D Volatility
Risk Regime
0.71β · 48% Vol 1.40β · 62% Vol Lower Realized Risk NDRA
Unified Institutional Score
Composite Signal
44.7 / 100 (HOLD) 45.7 / 100 (HOLD) Higher Composite DARE
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.4M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$8.0M ($104,744 Net Debt (0.26x D/E)) -$12M ($12M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NDRA +12.63 pp
NDRA: -6.75% · DARE: -19.38%
3M Horizon NDRA +21.95 pp
NDRA: -2.0% · DARE: -23.95%
6M Horizon NDRA +54.01 pp
NDRA: -18.3% · DARE: -72.31%
1Y Horizon NDRA +36.37 pp
NDRA: -32.72% · DARE: -69.09%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NDRA Revenue DARE Revenue NDRA Op. Margin DARE Op. Margin Margin Leader
FY2014 N/A $0M N/A -29177.5% DARE
FY2016 $0M $0M -347.5% -82.3% DARE
FY2017 $0M N/A -1315.6% N/A NDRA
FY2018 $0M N/A -146080.5% N/A NDRA
FY2022 N/A $10M N/A -313.9% DARE
FY2023 N/A $0M N/A -1101.9% DARE
FY2024 N/A $0M N/A -239692.2% DARE
FY2025 N/A $0M N/A -1315.5% DARE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NDRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NDRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DARE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DARE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NDRA Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $6.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DARE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $12.9M market capitalization and -813.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NDRA vs DARE Key Questions & Quantitative Answers

As of Nov 16, 2026, ENDRA Life Sciences Inc. (NDRA) captures the overall head-to-head institutional edge over Dare Bioscience, Inc. (DARE) on higher Unified Composite conviction (44.7/100 HOLD vs. 45.7/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality), while DARE wins 3–1 across the 6-pillar growth and valuation breakdown. NDRA trades at $4.42 (N/M Forward P/E, 0.0% operating margin) versus DARE at $0.58 (1.3x Forward P/E, -813.4% operating margin). Composite vs. Pillar Nuance: While DARE currently prints a higher short-term Unified Composite Score (45.7/100 HOLD vs. NDRA 44.7/100 HOLD), NDRA captures the overall institutional head-to-head verdict (4–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -813.4% operating margin) and revenue trajectory (+0.0% vs. +499.6% YoY). Technical & Structure Timing Caution: NDRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile DARE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DARE leads the Growth & Scale pillar: NDRA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DARE at +499.6% YoY revenue growth and +0.0% YoY earnings growth on $1.4M TTM revenue (N/A gross margin, -813.4% operating margin). Across the 8-period historical trajectory (FY2014 to FY2025), NDRA cumulative revenue shifted N/A while DARE shifted N/A. In operating R&D and SG&A reinvestment, NDRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DARE.

DARE screens cheaper on headline valuation multiples. NDRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas DARE trades at 1.3x Forward P/E, 1.3x Trailing P/E, N/M PEG, and 1.0x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NDRA (-152.0% ROE) versus DARE (-2543.1% ROE) capital efficiency.

In options market volatility and institutional positioning, NDRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 48% Vol realized risk). By comparison, DARE carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.40β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.